Bihua Chen's Net Worth

$0

Who is Bihua Chen?

Bihua Chen does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Corbus Pharmaceuticals Holdings, Inc., MoonLake Immunotherapeutics, Turning Point Therapeutics, Inc., Vigil Neuroscience, Inc., Prometheus Biosciences, Inc., Ambrx Biopharma, Inc., Design Therapeutics, Inc., Kezar Life Sciences, Inc., Icosavax, Inc., Atea Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Ventyx Biosciences, Inc., Axonics Modulation Technologies, Inc., Tyra Biosciences, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Verve Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., Apellis Pharmaceuticals, Inc., Immuneering Corp, Pyxis Oncology, Inc., Elevation Oncology, Inc., PROTEOSTASIS THERAPEUTICS, INC., BioAtla, Inc., Ambrx Biopharma Inc., Biomea Fusion, Inc., Rain Therapeutics Inc., Akouos, Inc., Cellectar Biosciences, Inc., Olema Pharmaceuticals, Inc., Clearside Biomedical, Inc., GreenLight Biosciences Holdings, PBC, CONSTELLATION PHARMACEUTICALS INC, EyePoint Pharmaceuticals, Inc., and Helix Acquisition Corp. II.

SEC CIK

Bihua Chen's CIK is 0001599214

Past Insider Trading and Trends

2022 was Bihua Chen's most active year for acquiring shares with 2 total transactions. Bihua Chen's most active month to acquire stocks was the month of May. 2023 saw Bihua Chen paying a total of $0.00 for 66,989 shares, this is the most they've acquired in one year.